Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The use of immune modulating drugs for the treatment of multiple sclerosis.
In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology.
Neurological and psychiatric disorders as a neuroglial failure.
Ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, inhibits proliferation and differentiation of th17 cells.
Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.
Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system.
Lower urinary tract symptoms associated with neurological conditions: Observations on a clinical sample of outpatients neurorehabilitation service.
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.
Role of Rho Kinase and Fasudil on Synaptic Plasticity in Multiple Sclerosis.
FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.
Illuminating vitamin D effects on B-cells - the multiple sclerosis perspective.
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.
The magnetic resonance imaging spectrum of Pelizaeus-Merzbacher disease: A multicenter study of 19 patients.
Neurological involvement in primary sjögren syndrome: a focus on central nervous system.
Central canal ependymal cells proliferate extensively in response to traumatic spinal cord injury but not demyelinating lesions.
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.
Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
High dose antigen treatment with a peptide epitope of myelin basic protein modulates T cells in multiple sclerosis patients.
A 17 year-old girl with a demyelinating disease requiring mechanical ventilation: a case report.
Differences between users and non-users of complementary and alternative medicine among people with multiple sclerosis in Denmark: A comparison of descriptive characteristics.
Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Plasma homocysteine levels in patients with multiple sclerosis in the Greek population.
Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis.
PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE.
Pages
« first
‹ previous
…
550
551
552
553
554
555
556
557
558
…
next ›
last »